How India Exports Aspirin to the World

In the United States, aspirin is regulated by the Food and Drug Administration (FDA). As a well-established drug, numerous Abbreviated New Drug Applications (ANDAs) have been approved for generic versions of aspirin, reflecting its widespread acceptance and use. The FDA's Orange Book provides a comprehensive list of these approved ANDAs, indicating the extensive generic competition in the market.

Regarding import alerts, the FDA issues these to prevent the entry of products that appear to violate regulations. As of March 2026, there are no specific import alerts related to aspirin from India. However, manufacturers and exporters must remain vigilant, as the FDA can impose import alerts if products are found to be non-compliant with U.S. standards. The regulatory pathway for aspirin involves compliance with the FDA's Current Good Manufacturing Practice (CGMP) regulations and ensuring that all labeling and marketing practices adhere to FDA guidelines. Given the 327 active Indian exporters, maintaining stringent quality control measures is imperative to ensure continued market access.

In the European Union (EU) and the United Kingdom (UK), aspirin is subject to regulation by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Marketing authorization for aspirin-containing products requires adherence to the EU's Good Manufacturing Practice (GMP) standards. The EMA has approved various formulations of aspirin, both as monotherapy and in combination with other agents. For instance, the combination of clopidogrel and acetylsalicylic acid has been authorized for the prevention of atherothrombotic events. Manufacturers exporting to these regions must ensure compliance with the respective regulatory requirements, including obtaining the necessary marketing authorizations and adhering to GMP standards.

Aspirin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. This inclusion mandates that member countries ensure its availability and affordability. Additionally, aspirin must comply with international pharmacopoeia standards, including those set forth by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures the quality, safety, and efficacy of aspirin products in the global market.

In India, aspirin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including aspirin, to ensure affordability. Manufacturers intending to export aspirin must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring that domestic supply is not adversely affected by export activities.

Aspirin, having been in use for over a century, is no longer under patent protection. This lack of exclusivity has led to a highly competitive market with numerous generic manufacturers producing and exporting aspirin globally. The absence of patent constraints facilitates easier market entry for new manufacturers but also necessitates stringent quality control to maintain market share.

In the past 12 months, several developments have impacted the aspirin market:

1. API Price Fluctuations (June 2025): The Directorate General of Foreign Trade (DGFT) reported a 10% increase in the price of aspirin's active pharmaceutical ingredient (API) due to supply chain disruptions.

2. New Generic Approvals (September 2025): The FDA approved three new ANDAs for generic aspirin products, increasing competition in the U.S. market.

3. Policy Changes in Export Regulations (December 2025): The Indian Ministry of Commerce and Industry revised export policies, requiring additional documentation for pharmaceutical exports to ensure quality compliance.

4. EU GMP Certification (February 2026): An Indian manufacturer received EU GMP certification, facilitating easier access to European markets.

5. WHO Prequalification (March 2026): A leading Indian pharmaceutical company achieved WHO prequalification for its aspirin product, enhancing its credibility in international tenders.

These developments highlight the dynamic nature of the aspirin market and the importance of staying abreast of regulatory changes and market trends.

India's pharmaceutical industry, including aspirin production, heavily relies on imports for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs), with over 70% sourced from China. This dependency exposes the supply chain to risks such as geopolitical tensions and trade restrictions. For instance, in July 2025, disruptions in Chinese supply chains led to a temporary shortage of critical APIs in India, highlighting the vulnerability of relying on a single source.

To mitigate these risks, the Indian government launched the Production Linked Incentive (PLI) Scheme for Bulk Drugs in July 2020, aiming to promote domestic manufacturing of critical KSMs, DIs, and APIs. By September 2025, the scheme had resulted in cumulative sales of ₹2,315 crore, including exports of ₹508 crore, thereby avoiding imports worth ₹1,807 crore. However, as of March 2026, aspirin's KSMs are not yet produced domestically under this scheme, leaving the supply chain susceptible to external disruptions.

Our proprietary trade data indicates that the top five Indian exporters account for 32.3% of aspirin exports, with RECKITT BENCKISER (INDIA) PRIVATE LIMITED leading at a 9.9% share. This moderate concentration suggests a relatively diversified supplier base, reducing the risk associated with single-source dependency.

The PLI Scheme for Pharmaceuticals, initiated in March 2021, aims to enhance domestic manufacturing capabilities. By September 2025, the scheme had attracted a committed investment of ₹17,275 crore, surpassing the initial target, and resulted in cumulative sales of ₹2,615 crore. While this initiative strengthens the overall pharmaceutical sector, its direct impact on aspirin production remains limited, as aspirin is not currently prioritized under the scheme.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Recent geopolitical tensions in these regions have led to increased shipping costs and delays. For example, in August 2025, escalated conflicts in the Strait of Hormuz disrupted maritime traffic, affecting the timely delivery of pharmaceutical shipments.

Additionally, ongoing US-China trade tensions have impacted the availability and pricing of Chinese-sourced KSMs and APIs. In September 2025, the FDA issued alerts regarding potential shortages of certain medications due to these trade disputes, underscoring the fragility of the global pharmaceutical supply chain.

• Diversify Sourcing: Identify and qualify alternative suppliers for KSMs and APIs from regions other than China to reduce dependency on a single source.

• Enhance Domestic Production: Advocate for the inclusion of aspirin-related KSMs and APIs in the PLI Scheme to promote local manufacturing and strengthen supply chain resilience.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events affecting key shipping routes and implement contingency plans to mitigate potential disruptions.

• Strengthen Supplier Relationships: Develop strategic partnerships with multiple suppliers to ensure a stable and reliable supply chain, reducing the impact of any single supplier's disruption.

• Invest in Inventory Management: Maintain adequate safety stock levels of critical raw materials and finished products to buffer against supply chain interruptions.

RISK_LEVEL: MEDIUM